Your session is about to expire
← Back to Search
Nicotinamide for Chronic Lymphocytic Leukemia and Skin Cancer
Study Summary
This trial is a study to see if a drug can prevent a type of skin cancer in people with a certain type of blood cancer.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 2 trial • 46 Patients • NCT03061474Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have not taken acitretin or other oral retinoids in the last 6 months.You are not expected to live for more than 2 years.I need to keep taking carbamazepine.I have had at least one non-melanoma skin cancer in the past 5 years.I have or had a peptic ulcer.I have an ongoing infection that isn't under control.I have severe digestive issues that affect how my body absorbs medication.I have not had skin treatments for AKs in the last 4 weeks.I am not pregnant or I am post-menopausal.My skin cancer covers large areas, making it hard to count new cancers.My diabetes is not under control.I have been diagnosed with CLL or SLL according to the latest criteria.My liver is functioning well, with normal bilirubin levels.I have stopped taking certain medications as required before starting treatment.I have had chemotherapy with specific drugs in the last 6 months.I have taken nicotinamide or niacin supplements in the last 4 weeks.You have had a severe allergic reaction to the study drug or any of its parts in the past.I agree to use effective birth control during the study.I had a stem cell transplant from a donor within the last 6 months.You have a liver condition called Gilbert's Syndrome with specific levels of bilirubin in your blood.I have had an organ transplant and am on immunosuppressive drugs.I am 18 years old or older.I have HIV with a detectable viral load in the last 6 months.Your liver enzymes (AST and ALT) should be less than 3 times the normal limit.
- Group 1: Arm 2: Placebo
- Group 2: Treatment: all patients
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How can the potential risk-to-benefit ratio be gauged for Nicotinamide use?
"Assessing safety, Nicotinamide was deemed to be a 2 on our rating scale due to the fact it is currently undergoing Phase 2 clinical trials. This indicates that while there are some data demonstrating its security, no evidence has been found yet supporting its efficacy."
In what conditions is Nicotinamide typically utilized?
"Nicotinamide is typically employed to help supplement a patient's nutrition. It can also be useful in treating dietary and nutritional therapies, vitamin deficiency, and macrocytic anemia."
What is the upper limit of individuals being studied in this experiment?
"Indeed, the clinicaltrials.gov website states that this investigation is currently enrolling individuals. The trial was announced on August 5th 2021 and most recently updated January 14th 2022 with 86 participants necessary at one site."
Are there any vacancies available in this trial for participants?
"As of the time of this writing, patients are being invited to take part in the trial. The protocol was initially posted on August 5th 2021 and amended as recently as January 14th 2022."
Share this study with friends
Copy Link
Messenger